News
BIOVF
46.00
NaN%
--
Sobi Taps Former Ericsson CEO Börje Ekholm as Next Chair
TipRanks · 1h ago
Swedish Orphan price target raised to SEK 600 from SEK 575 at H.C. Wainwright
TipRanks · 1d ago
Swedish Orphan Biovitrum upgraded to Buy from Hold at Pareto
TipRanks · 2d ago
Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 6.96, revenue of SEK 9.12B; updates FY2026 outlook
Seeking Alpha · 2d ago
Sobi Q3 2026 report: Underpinning a strong growth momentum
PR Newswire · 2d ago
Sobi Posts Double-Digit Q3 Growth as Rare Disease Portfolio Expands
TipRanks · 2d ago
Swedish Orphan Biovitrum downgraded to Hold from Buy at Nordea
TipRanks · 10/22 08:56
Harry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth Upside
TipRanks · 10/20 08:35
Lilly, Pfizer, J&J among winners of EU drug recommendations this month
Seeking Alpha · 10/16 12:33
Sobi Adjusts Share Capital to Support Employee Incentive Programme
TipRanks · 09/30 06:35
Berenberg Bank Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)
TipRanks · 09/14 06:45
Sobi: Advancing Pacritinib Pipeline Supports Asymmetric Upside With Buy Rating and Maintained SEK575 Target
TipRanks · 09/10 11:15
Sobi Completes Class C Share Issue to Fund Employee Incentive Programme
TipRanks · 08/31 10:36
Aspaveli’s Enhanced Kidney Data Supports Global Growth; Analyst Reiterates Buy Rating and Maintains $575 Price Target
TipRanks · 08/24 10:25
Buy Rating Reiterated on Sobi as Diversified Pipeline and Lacutamab Partnership Support Upside; 12‑Month SEK575 Price Target Unchanged
TipRanks · 08/10 15:35
Sobi partners with Innate Pharma in $580m lacutamab deal to expand rare cancer portfolio
TipRanks · 08/10 06:33
Sobi Reaffirmed at Buy as Analyst Trims Target to SEK560 Amid Long-Term Competitive Pressures
TipRanks · 08/04 16:06
Mitchell Kapoor Reiterates Buy on Swedish Orphan Biovitrum, Maintains SEK575 12-Month Price Target Amid Solid Late-Stage Pipeline and CEO Transition
TipRanks · 08/03 18:55
Sobi CEO Guido Oelkers to Step Down in Early 2027
TipRanks · 08/03 05:33
Swedish Orphan Biovitrum price target raised to SEK 575 at Berenberg
TipRanks · 07/17 16:50
More
Webull provides a variety of real-time BIOVF stock news. You can receive the latest news about Swedish Orphan Biovitrum Ab through multiple platforms. This information may help you make smarter investment decisions.
About BIOVF
Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.